2014年ESC肥厚型心肌病猝死预防指南的国际外部验证研究(EVIDENCE-HCM)
本研究为观察性回顾性纵向队列研究,纳入来自美国、欧洲、中东和亚洲的3703例肥厚型心肌病患者,外部验证2014年ESC基于HCM Risk-SCD模型的猝死风险分层推荐。结果显示模型校准斜率1.02、C指数0.70,预测5年风险≥6%者实际猝死发生率为8.9%,提示该模型可准确识别高危患者并指导ICD治疗。
要点
- HCM Risk-SCD模型外部验证校准良好,C指数0.70。
- 预测5年风险≥6%者实际猝死发生率为8.9%。
- 每13例ICD植入可潜在挽救1例猝死。
核心结论
- HCM Risk-SCD模型提供准确的预后信息,可用于靶向ICD治疗最高危猝死患者。
研究设计与样本
- 观察性、回顾性、纵向队列研究,纳入来自美国、欧洲、中东和亚洲的3703例肥厚型心肌病患者。
主要发现
- 验证显示校准斜率1.02(95%CI 0.93-1.12),C指数0.70(95%CI 0.68-0.72),D统计量1.17(95%CI 1.05-1.29)。
- 完整病例分析(n=2147;5年44例猝死终点)中,预测5年风险<4%者(n=1524;71%)实际5年猝死发生率为1.4%(95%CI 0.8-2.2)。
- 预测风险≥6%者(n=297;14%)实际5年猝死发生率为8.9%(95%CI 5.96-13.1)。
- 预测5年猝死风险≥6%的患者中,每13例ICD植入可潜在挽救1例猝死。
关键数值与推荐
- 2014年ESC指南推荐基于HCM Risk-SCD模型估计5年猝死风险以指导预防性ICD植入。
- 预测5年风险<4%者实际猝死发生率1.4%(95%CI 0.8-2.2)。
- 预测5年风险≥6%者实际猝死发生率8.9%(95%CI 5.96-13.1)。
临床怎么用
- 临床可采用HCM Risk-SCD模型评估肥厚型心肌病患者5年猝死风险。
- 对预测5年风险≥6%的患者,考虑预防性ICD植入以降低猝死风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter defibrillator is challenging. In 2014, the European Society of Cardiology proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally validate the 2014 European Society of Cardiology recommendations in a geographically diverse cohort of patients recruited from the United States, Europe, the Middle East, and Asia. METHODS: This was an observational, retrospective, longitudinal cohort study. RESULTS: The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end point within 5 years of follow-up (5-year incidence, 2.4% [95% confidence interval {CI}, 1.9-3.0]). The validation study revealed a calibration slope of 1.02 (95% CI, 0.93-1.12), C-index of 0.70 (95% CI, 0.68-0.72), and D-statistic of 1.17 (95% CI, 1.05-1.29). In a complete case analysis (n= 2147; 44 SCD end points at 5 years), patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI, 0.8-2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI, 5.96-13.1) at 5 years. For every 13 (297/23) implantable cardioverter defibrillator implantations in patients with an estimated 5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD. CONCLUSIONS: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.
引用
- O'Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2017. PMID: 29191938. doi:10.1161/CIRCULATIONAHA.117.030437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。